Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Psoriasis cyclosporine

In rheumatoid arthritis, cyclosporine is used in severe cases that have not responded to methotrexate. Cyclosporine can be combined with methotrexate, but the levels of both drugs must be monitored closely. In psoriasis, cyclosporine is indicated for treatment of adult immunocompetent patients with severe and disabling disease for whom other systemic therapies have failed. Because of its mechanism of action, cyclosporine also has been used successfully in inflammatory bowel disease see Chapter 38). [Pg.913]

The first human kidney and bone marrow transplants using cyclosporine were reported in 1978. Oral or intravenous cyclosporine is an immunosuppressant for transplantation of these and other organs and investigations are underway for its possible use in a variety of autoimmune diseases including rheumatoid arthritis, severe psoriasis, and Crohn s disease. Dose-dependent nephrotoxicity (261—264) remains the primary limitation of the dmg and necessitates close monitoring of patients, including measurement of dmg levels in blood. Cyclosporine research has been reviewed (265—274). [Pg.159]

Cyclosporine and tacrolimus are calcineurin inhibitors that are administered as part of immunosuppressive regimens in kidney, liver, heart, lung, and bone marrow transplant recipients. In addition, they are used in autoimmune disorders such as psoriasis and multiple sclerosis. The pathophysiologic mechanism for ARF is renal vascular vasoconstriction.41 It often occurs within the first 6 to 12 months of treatment, and can be reversible with dose reduction or drug discontinuation. Risk factors include high dose, elevated trough blood concentrations, increased age, and concomitant therapy with other nephrotoxic drugs.41 Cyclosporine and tacrolimus are extensively metabolized by... [Pg.370]

Systemic therapies are seldom used for mild to moderate psoriasis, and are generally reserved for patients with moderate to severe psoriasis.17 29 Oral agents include sulfasalazine, acitretin, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, and hydroxyurea. Parenteral agents include the biologic response modifiers alefacept, efalizumab, etanercept, infliximab, and many others, currently at various stages of research or approval for psoriasis. [Pg.955]

Mycophenolate mofetil in doses of 1 to 1.5 g twice daily (maximum dose 3 g/day) is effective as adjunctive therapy in patients with resistant psoriasis on cyclosporine.29,38 As monotherapy, there may be some benefit in patients with moderate psoriasis and psoriatic arthritis, but not in severe psoriasis.29... [Pg.956]

Cyclosporine demonstrates immunosuppressive activity by inhibiting the first phase of T-cell activation. It also inhibits release of inflammatory mediators from mast cells, basophils, and polymorphonuclear cells. It is used in the treatment of both cutaneous and arthritis manifestations of severe psoriasis. The usual dose is between 2.5 and 5 mg/kg/day given in two divided doses. Adverse effects include nephrotoxicity, hypertension, hypomagnesemia, hyperkalemia, alterations in liver function tests, elevations of serum lipids, GI intolerance, paresthesias, hypertrichosis, and gingival hyperplasia. Cumulative treatment for more than 2 years may increase the risk of malignancy, including skin cancers and lymphoproliferative disorders. [Pg.206]

Sequential therapy involves rapid clearing of psoriasis with aggressive therapy (e.g., cyclosporine), followed by a transitional period in which a safer drug such as acitretin is started at maximal dosing. Subsequently, a maintenance period using acitretin in lower doses or in combination with UVB or PUVA can be continued. [Pg.208]

Hypersensitivity to polyoxyethylated castor oil (injection only see Warnings and Administration and Dosage), cyclosporine, or any component of the products Gengraf and Neoral in psoriasis or RA patients with abnormal renal function, uncontrolled hypertension, or malignancies Gengraf and A/eora/concomitantly with PUVA or DVB, methotrexate or other immunosuppressive agents, coal tar or radiation therapy in psoriasis patients. [Pg.1964]

It is a newer agent derived from Streptomyces hygroscopicus that binds immunophylin (same as in tacrolimus and cyclosporine). It is indicated in the management of psoriasis and uveoretinitis. [Pg.454]

Cyclosporin is usually given orally, although absorption is often unpredictable. The intravenous route is usually restricted to patients who cannot take the drug orally, because of the risk of anaphylactic reactions. Other uses of cyclosporin include psoriasis and severe, active rheumatoid arthritis when these do not respond to conventional treatment, and steroid-resistant nephrotic syndrome. [Pg.252]

Cyclosporine is used to prevent organ rejection after tissue transplantation. It is also used for rheumatoid arthritis, psoriasis and dry eyes (keratoconjunctivitis sicca). For... [Pg.90]

Stiller MJ, Pak GH, Kenny C, Jondreau L, Davis I, Wachsman S, Shupack JL. Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol 1992 27(3) 434-8. [Pg.665]

Grossman RM, Delaney RJ, Brinton EA, Carter DM, Gottlieb AB. Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol 1991 25(4) 648-51. [Pg.665]

Cyclosporine A absorption was evaluated following oral administration of the regular Sandimmun soft gelatin capsule and the Neoral microemulsion formulation to patients with psoriasis. The Neoral formulation showed 32% increased mean AUC value, increased Cmax, decreased tmax and reduced variability between patients (Figure 6.4) [42],... [Pg.119]

FIGURE 6.4 Individual plasma cyclosporine A profiles following oral administration of Neoral microemulsion formulation (a) and the regular Sandimmun soft gelatin capsule (b) in psoriasis patients. (From Erkko, P., et al., Br. J. Dermatol., 136, 82, 1997. With permission.)... [Pg.119]

Erkko, P., et al. 1997. Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis. Br J Dermatol 136 82. [Pg.129]

Cyclosporine Neoral, Sandimmune Kidney, liver, heart, lung, pancreas, bone marrow Psoriasis, rheumatoid arthritis, nephrotic syndrome... [Pg.594]

Cyclosporine is used to a somewhat lesser extent in treating autoimmune diseases, but it may be helpful in conditions such as psoriasis, rheumatoid arthritis, inflammatory bowel disease, and glomerulonephri-tiS.i5,32,63 as discussed in Chapter 32, cyclosporine has also been used in the early stages of type 1 diabetes mellitus to help control immune-mediated destruction of pancreatic beta cells, thus decreasing the severity of this disease in some patients.9... [Pg.595]

Voclosporin (ISA-247, R1524) 88 (Isotechnika) is being evaluated in a Phase III trial for the treatment of psoriasis,250 as well as a Phase III trial by Lux Biosciences as for the treatment of uveitis (coded as LX211, Luveniq ).251,252 In addition, voclosporin 88 has completed a Phase lib trial for the prevention of kidney graft rejection. Voclosporin 88253,254 is a slightly more potent but less toxic semi-synthetic derivative of the fungal-derived immunosuppressant cyclosporin A 89, which has the same mechanism of calcineurin inhibition. Cyclosporin A 89 was first isolated from Tolypocladium inflatum by workers at Sandoz and its structure was published in 1976.255,256... [Pg.341]

The type of lesion and whether the patient also has psoriatic arthritis are important issues in cleterinining therapy. Steroid topical creams, cyclosporine andmethotraxate are useful in treatment of psoriasis. Oral tazarotene, a non-biologic retinoid is pending FDA approval for moderate to severe psoriasis. As with most autoimmune disorder s, different patients respond differently and newer more targeted therapies are important goals. [Pg.290]

Cyclosporine is an important drug in preventing rejection after kidney, hver, heart and other organ transplantation (Haberal et al., 2004). Cyclosporine usually is combined with other immunosuppressives especially glucocorticoids and either azathioprine or mycophenolate mofedl and sirolimus (Krensky et al., 2005). In renal alio transplants it has improved graft acceptance in most clinics to 95 percent. In addition to its use in transplantation cyclosporine is used for the treatment of a number of autoimmune diseases. In autoimmune diseases, as might be anticipated, cyclosporine is most effective in those which are T cell mediated. These include several forms of psoriasis, rheumatoid arthritis refractive to all other therapy, uveitis, nephrotic syndrome and type I diabetes mellitus. [Pg.558]

Another recent pair of investigations have examined the application of electroporation to enhance the delivery of cyclosporin for the treatment of psoriasis. Compared to passive transport, single electroporative pulses resulted in up to a 60-fold enhancement in hairless rat skin permeability depending upon the vehicle used. [Pg.2750]

Korstanje MJ, BUo HJ, Stoof TJ. Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy. Br J Dermatol 1992 127(5) 501-4. [Pg.765]


See other pages where Psoriasis cyclosporine is mentioned: [Pg.955]    [Pg.532]    [Pg.424]    [Pg.1959]    [Pg.122]    [Pg.220]    [Pg.466]    [Pg.437]    [Pg.811]    [Pg.1191]    [Pg.1306]    [Pg.122]    [Pg.220]    [Pg.430]    [Pg.832]    [Pg.1339]    [Pg.1468]    [Pg.124]    [Pg.483]    [Pg.195]    [Pg.465]    [Pg.1472]    [Pg.2743]   
See also in sourсe #XX -- [ Pg.955 ]

See also in sourсe #XX -- [ Pg.1773 , Pg.1777 ]




SEARCH



Cyclosporin

Cyclosporin/cyclosporine

Cyclosporines

Cyclosporins

Cyclosporins Cyclosporin

Psoriasis

© 2024 chempedia.info